XBI

The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that tracks the S&P Biotechnology Select Industry Index, providing investors with exposure to the biotechnology sector of the U.S. stock market. Launched in 2006, XBI focuses on publicly traded companies engaged in the research, development, and commercialization of biotechnology products and services, including therapeutic drugs, diagnostic tools, and genetic engineering technologies. The fund holds a diversified portfolio of mid-cap and smaller biotech companies, distinguishing it from larger pharmaceutical firms by emphasizing pure-play biotechnology businesses. These underlying companies typically operate across various therapeutic areas such as oncology, immunology, infectious diseases, and rare genetic disorders, often focusing on innovative technologies like monoclonal antibodies, gene therapy, and personalized medicine. XBI serves as a benchmark for the broader biotechnology industry's performance, reflecting trends in drug development pipelines, regulatory approvals, clinical trial outcomes, and scientific breakthroughs. The biotechnology sector itself represents a critical component of modern healthcare innovation, with companies working to develop next-generation treatments and cures for previously incurable diseases through advanced biological and molecular research.